Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSH | P09668 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1405950 | 0.89 | CTSS (0.46) | CTSSRENPSMB8CTSBCTSK | |
| SCHEMBL1406173 | 0.85 | CTSS (0.40) | CTSSPSMB8CTSBCTSL | |
| SCHEMBL1406331 | 0.84 | MMP2 (0.41) | CTSSMMP2MMP9MMP8REN | |
| SCHEMBL1405946 | 0.84 | CTSS (0.44) | CTSSPSMB8 | |
| SCHEMBL6839187 | 0.82 | KDM4E (0.34) | CTSSKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL1406160 | 0.81 | CTSS (0.37) | CTSSRENPSMB8 | |
| SCHEMBL2302161 | 0.79 | CTSS (0.45) | CTSSMMP2MMP9MMP8REN | |
| SCHEMBL1406179 | 0.77 | GAA (0.36) | MMP2MMP9MMP8RENTACR1 | |
| SCHEMBL9631257 | 0.74 | POLB (0.53) | CTSSMMP2MMP9MMP8TACR1 | |
| Leucine SCHEMBL1406254 | 0.74 | MMP2 (0.50) | CTSSMMP2MMP9MMP8CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355910-B1 | FORMULATION OF BORONIC ACID COMPOUNDS | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2011-03-09 | — | — | EP | claimed |
| US-20040138411-A1 | Formulation of boronic acid compounds | Government of U.S.A., represented by the Secretary Department of Health & Human Services | 2004-07-15 | — | — | US | claimed |
| US-20040063623-A1 | Formulation of boronic acid compounds | GOV. OF THE U.S.A. REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SVCS. | 2004-04-01 | — | — | US | claimed |
| US-6713446-B2 | BORONIC ACID COMPOUNDS OBTAINED BY LYOPHILIZATION OF AN AQUEOUS MIXTURE OF THE BORONIC ACID COMPOUND AND A SUGAR HAVING AT LEAST TWO HYDROXYL GROUPS; SHELF LIFE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-03-30 | — | — | US | claimed |
| US-6699835-B2 | BORON COMPOUND FOR USE IN THE TREATMENT OF STROKE, HEART DEFECTS, INFLAMMATION, AUTOIMMUNE AND CANCER DISEASE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-03-02 | — | — | US | claimed |
| EP-1360189-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2003-11-12 | — | — | EP | claimed |
| EP-1355910-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | The United States of America, represented by the Secretary, Department of Health and Human Services (US) | 2003-10-29 | — | — | EP | claimed |
| US-20020188100-A1 | Formulation of boronic acid compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | claimed |
| US-20020169114-A1 | Formulation of boronic acid compounds | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-11-14 | — | — | US | claimed |
| WO-2002059130-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-08-01 | — | — | WO | claimed |
| WO-2002059131-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-08-01 | — | — | WO | claimed |
| EP-2251344-B2 | FORMULATION OF BORONIC ACID COMPOUNDS | THE UNITED STATES OF AMERICA REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3078667-B1 | FORMULATION OF BORONIC ACID COMPOUNDS | THE UNITED STATES OF AMERICA REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-3078667-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | The United States of America, represented by the Secretary, Department of Health and Human Services (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2251344-B1 | FORMULATION OF BORONIC ACID COMPOUNDS | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-1355910-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | The United States of America, represented by the Secretary, Department of Health and Human Services (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20020188100-A1 | Formulation of boronic acid compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | disclosed |
| US-20020169114-A1 | Formulation of boronic acid compounds | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-11-14 | — | — | US | disclosed |
| WO-2002059130-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059131-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188100-A1 | Formulation of boronic acid compounds | SLC10A2, BTD, SLC10A1 | CTSS 4167/4885MMP2 4832/4885MMP9 4777/4885 |
| US-20040138411-A1 | Formulation of boronic acid compounds | SLC10A2, SLC10A1, BTD | CTSS 4208/4885MMP2 4872/4885MMP9 4867/4885 |
| US-20040063623-A1 | Formulation of boronic acid compounds | SLC5A1, FBP1, BBC3 | CTSS 3297/4885MMP2 4276/4885MMP9 4373/4885 |
| US-20020169114-A1 | Formulation of boronic acid compounds | SLC5A1, FBP1, BBC3 | CTSS 3297/4885MMP2 4276/4885MMP9 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.